Sangamo and Biogen are teaming up to develop gene therapies for Parkinson’s and Alzheimer’s disease, as well as another neuromuscular disease target and up to nine undisclosed neurological disorders. The collaboration will leverage Sangamo’s proprietary zinc finger protein (ZFP) technology, designed to target almost any sequence…
A blood test may be able to predict early cognitive decline in people with Parkinson’s disease by measuring the length of chromosomal telomeres (the “tips” of chromosomes) in immune cells and the presence of inflammatory markers, a study shows. The study, “…
Table tennis may offer benefits as a form of Parkinson’s physical therapy, according to a preliminary study that showed lessening of symptoms in patients who participated weekly in the sport for six months. “Pingpong, which is also called table tennis, is a form of aerobic exercise that has been…
Treatment with cerebral dopamine neurotrophic factor (CDNF), developed by Herantis Pharma, was safe and well-tolerated among patients with advanced-stage Parkinson’s disease, according to topline results from a Phase1/2 clinical trial. The therapy also showed promise in measures of dopaminergic function in some patients. CDNF is based…
Dizziness — including sensations of fainting, imbalance, and vertigo — is common among Parkinson’s patients and may be a potential non-motor symptom of early-stage disease possibly associated with cognitive decline, a study has found. Typically, dizziness episodes are short and frequent, lasting seconds to minutes and occurring several times…
People with Parkinson’s disease may have higher levels of selenium — a mineral with antioxidant properties — in their cerebrospinal fluid, the liquid that surrounds the brain and spinal cord, a study suggests. The research, “Selenium level does not differ in blood but…
A new potential target for treating Parkinson’s, a protein named Drp1, has been identified using a rat model of the disease, a study reported. The target was found to play a central role in the underlying cause of the degeneration and inflammation of nerve cells…
Likely cognitive decline, dementia risk, and the severity of motor symptoms in Parkinson’s disease might be tracked by measuring the amount of iron content in the brain, a study reports. These finding were described in the study “Brain iron deposition is linked with cognitive severity in Parkinson’s disease,”…
Scientists have developed a new cellular model that can help reconstruct the entire process of Lewy body formation — a key event that underlies neurodegeneration in Parkinson’s disease — and that could potentially be used to evaluate the effect of therapeutics on the toxic protein buildup observed during this…
Annovis Bio’s lead investigative therapy ANVS401 (also known as Posiphen) targeting protein buildup in the brain has been granted a U.S. patent as a way of treating Parkinson’s disease, Lewy body dementia, and other Lewy body disorders. The company, previously known as QR Pharma,…
Get regular updates to your inbox.
